Abstract
In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Current Vascular Pharmacology
Title:Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Volume: 12 Issue: 4
Author(s): Manfredi Rizzo, Milan Obradovic, Milica Labudovic-Borovic, Dragana Nikolic, Giuseppe Montalto, Ali A. Rizvi, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Abstract: In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.
Export Options
About this article
Cite this article as:
Rizzo Manfredi, Obradovic Milan, Labudovic-Borovic Milica, Nikolic Dragana, Montalto Giuseppe, Rizvi A. Ali, Mikhailidis P. Dimitri and Isenovic R. Esma, Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome, Current Vascular Pharmacology 2014; 12 (4) . https://dx.doi.org/10.2174/1570161111999131205160756
DOI https://dx.doi.org/10.2174/1570161111999131205160756 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Adipocytokines in Non-functional Adrenal Incidentalomas and Relation with Insulin Resistance Parameters
Endocrine, Metabolic & Immune Disorders - Drug Targets Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Zinc Hydrogen Sulfate Promoted Multi-component Preparation of Highly Functionalized Piperidines
Letters in Organic Chemistry Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Results of Controlled Clinical Trials Comparing “Guideline Exposed” and “Guideline Naive” Physicians in the Treatment of Depression, Hypertension,and Diabetes: What can be Learned?
Current Psychiatry Reviews A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Estimating Alzheimer’s Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia
Current Alzheimer Research Sleep in Pulmonary Hypertension
Current Respiratory Medicine Reviews From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Effect of Chronic Melatonin Administration on Several Physiological Parameters from Old Wistar Rats and Samp8 Mice
Current Aging Science Recent Advances in Clinical Immunology, Endocrine & Metabolic Drugs: An Editorial Overview
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Editorial:Genomics and Epigenomics of Tumor and Aging Cells
Current Genomics